Welcome to the Orozco Laboratory

Our research group focuses on developing and improving antibody therapies for leukemia and lymphoma patients, with the goal of translating laboratory findings into the clinic. In the laboratory, we are working to increase the effectiveness of radioimmunotherapy by developing “pre-targeted” methods for more selectively delivering radiation to tumor sites. We are also developing therapies that combine radioimmunotherapy and hematopoietic stem cell transplantation (HCT), with the goal of decreasing toxicities while increasing anti-cancer efficacy.  One innovative application of our work is to replace total body irradiation and high-dose chemotherapy with radioimmunotherapy in conditioning regimens for partially matched (haploidentical) allogeneic HCT, as a means to reduce toxicity and thereby make HCT a potentially curative option for more patients.